Phase I/pharmacokinetic study of intraperitoneal teniposide (VM 26)
- 1 May 1989
- journal article
- research article
- Published by Elsevier in European Journal of Cancer and Clinical Oncology
- Vol. 25 (5) , 815-820
- https://doi.org/10.1016/0277-5379(89)90126-0
Abstract
No abstract availableThis publication has 23 references indexed in Scilit:
- Escalating dose regimen of intraperitoneal mitoxantrone: Phase I study—clinical and pharmacokinetic evaluationEuropean Journal of Cancer and Clinical Oncology, 1988
- Phase I/pharmacokinetic study of thioguanine administered as a 48-hour continuous intraperitoneal infusion.Journal of Clinical Oncology, 1988
- Phase I and pharmacokinetic study of high volume intraperitoneal aclacinomycin ? A (Aclarubicin)Investigational New Drugs, 1987
- Quantification of teniposide in human serum by high-performance liquid chromatography with electrochemical detectionJournal of Chromatography B: Biomedical Sciences and Applications, 1986
- Phase I and pharmacologic studies of intraperitoneal leucovorin and 5-fluorouracil in patients with advanced cancer.Journal of Clinical Oncology, 1986
- Hypersensitivity reactions to teniposide (VM-26): an analysis.Journal of Clinical Oncology, 1986
- Pharmacokinetics and efficacy of i.v. and i.p. VM26 chemotherapy in mice bearing krebs II ascitic tumorsEuropean Journal of Cancer and Clinical Oncology, 1986
- Pharmacokinetics of teniposide (VM 26) after IV administration in serum and malignant ascites of patients with ovarian carcinomaCancer Chemotherapy and Pharmacology, 1985
- Intraperitoneal cytosine arabinoside therapy in ovarian carcinoma.Journal of Clinical Oncology, 1984
- Comparison of the human pharmacokinetics of VM-26 and VP-16, two antineoplastic epipodophyllotoxin glucopyranoside derivativesPublished by Elsevier ,1975